Search for Learning Modules
The Endocannabinoid System in Health and Disease
The endocannabinoid system is a major regulatory system in the body, responsible for regulating nearly all our bodily systems and functions. In this foundation module, neuroscientist Dr Elisabeth Philipps presents an overview of the endocannabinoid system, covering its components, distribution and roles including in stress modulation, pain, inflammation, neuroinflammation and more.
This module is suitable for healthcare practitioners and others with a background in biomedical sciences.
Dr Elisabeth Philipps, PhD
50
Cannabis as an Orchestra of Components for a Multitude of Conditions
This learning module presents an overview of medicinal cannabis by one of Israel’s leading experts, Dr David (Dedi) Meiri. Dr Meiri explores the endocannabinoid system and the many constituents of cannabis, and shares some of his research findings including evidence of specificity of cannabis cultivars in relation to cancer cells, and demonstrating the concept of polypharmacy in relation to cannabis.
Dr Dedi Meiri
50
Case Studies in Dementia and Palliative Care
Dr Zac Baran
50
Medicinal Cannabis in Paediatric Developmental Disorders
Daryl Efron
50
Overview of Medicinal Cannabis: Foundations
In this learning module, we explore what medicinal cannabis is, including its history of use, the major components of cannabis (cannabidiol [CBD], tetrahydrocannabinol [THC], terpenes), and the major therapeutic actions of THC and CBD and their mechanisms of action. We also examine what people are using medicinal cannabis for, evidence of its efficacy and briefly cover safety in relation to THC and CBD.
This learning module is suitable for healthcare practitioners with an interest in learning about medicinal cannabis.
Prof. Kylie O'Brien
50
Cannabis Pharmacokinetics
In this presentation, pharmacology expert Associate Professor Ali Seyfoddin (New Zealand) takes us through the pharmacokinetics of medicinal cannabis, covering the routes of delivery of cannabis (inhalation, oral, buccal, rectal and transdermal routes) and the associated absorption characteristics, distribution, metabolism and elimination. THC bioavailability, time for maximum plasma concentrations, and potential for drug-cannabinoid interactions is also examined.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Ali Seyfoddin
50
Cannabis and Driving
In this presentation, Associate Professor Ali Seyfoddin gives a summary of the safety aspects of cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD) including common side effects, drug-cannabis interactions, and contraindications. He also explores some of the scientific evidence of safety of cannabis in the treatment of specific illnesses, as well as safety in relation to long-term use.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Dr Thomas Arkell
50
Prescribing Cannabis for Symptom Management in Cancer Patients
Cancer is rapidly becoming the number one cause of mortality in many countries. Increasingly people diagnosed with cancer are turning to medicinal cannabis to treat symptoms/signs associated with cancer and its treatments. In this presentation, Associate Professor Judith Professor of the Chris O’Brien Lifehouse Comprehensive Cancer Centre, shares her experience in cancer and cancer treatment symptom management, including its use in treating refractory symptoms in advanced cancer.
This presentation assumes an understanding of the endocannabinoid system and how CBD and THC work. This presentation is pitched at the level of healthcare practitioners and those with a background in biomedical sciences.
Judith Lacey
50
Safety of Medicinal Cannabis
In this presentation, Associate Professor Ali Seyfoddin gives a summary of the safety aspects of cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD) including common side effects, drug-cannabis interactions, and contraindications. He also explores some of the scientific evidence of safety of cannabis in the treatment of specific illnesses, as well as safety in relation to long-term use.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Ali Seyfoddin
50
Safety of Medicinal Cannabis
In this presentation, you will learn about the safety aspects of cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD) including common and rarer side effects, effects on blood pressure and heart rate, toxicity and drug-cannabis/THC/CBD interactions. Safety of terpenes will also be covered.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Prof. Kylie O'Brien
50
Audio Module: Considering Cannabis with Nick Lintzeris
Prof. Nick Lintzeris
50
CB2 Receptors: Webinar with Dr Philip Blair
In this learning module, leading cannabis clinician and expert, Dr Philip Blair MD explores how key phytocannabinoids can modulate the various aspects of our immune system. Beginning with a brief overview of the expanded endocannabinoid system, we learn about various stresses on the ECS such as oxidative stress, and the various ways in which we naturally modulate our immune system, before turning to those modulators of the ECS- phytocannabinoids, N-acyl ethanolamines and other components of cannabis. We also learn about how phytocannabinoids, in particular CBD modulate inflammation, immune cells, oxidative stress and the neuro-immune axis as well as affecting zinc. Dr Blair also discusses evidence for the immune suppression versus immune enhancing effects of CBD.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and a basic understanding of medicinal cannabis pharmacodynamics.
Dr Philip Blair
50
Cannabis and the Immune System
In this learning module, leading cannabis clinician and expert, Dr Philip Blair MD explores how key phytocannabinoids can modulate the various aspects of our immune system. Beginning with a brief overview of the expanded endocannabinoid system, we learn about various stresses on the ECS such as oxidative stress, and the various ways in which we naturally modulate our immune system, before turning to those modulators of the ECS- phytocannabinoids, N-acyl ethanolamines and other components of cannabis. We also learn about how phytocannabinoids, in particular CBD modulate inflammation, immune cells, oxidative stress and the neuro-immune axis as well as affecting zinc. Dr Blair also discusses evidence for the immune suppression versus immune enhancing effects of CBD.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and a basic understanding of medicinal cannabis pharmacodynamics.
Dr Philip Blair
50
Cannabis use disorder in medical cannabis patients: implications for clinical practice
Cannabis use disorder is not uncommon amongst recreational cannabis users. However, there is also a risk that some patients prescribed medicinal cannabis could also become dependent or addicted. Patients may also suffer from cannabis withdrawal when stopping its use. Healthcare practitioners need to be aware of these risks, and how to manage them. In this presentation, addiction medicine specialist and cannabis prescriber Professor Nicholas Lintzeris discusses the issue of cannabis addiction and cannabis use disorder, as well as withdrawal from cannabis, including implications for clinical practice.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Prof. Nick Lintzeris
50
Medical Cannabis & the Treatment of Cannabis and Other Substance Use Disorders
Prof. Nick Lintzeris
50
Caryophyllene: A key terpene found in many plants including cannabis.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Dr Philip Blair
50
Experiential Knowledge of Growers and Intersections with Science: Typing of Cannabis Cultivars According to Aroma & Terpenes
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Kevin Jodrey, Jean Talleyrand & John Abrams
50
Rheumatoid Arthritis and Medicinal Cannabis
In this presentation, medicinal cannabis expert Dr Philip Blair MD explores rheumatoid arthritis, its pathogenesis, how the endocannabinoid system is involved, and evidence that key phytocannabinoids including CBD, THCA and endocannabinoid-like substances palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) may be useful in the treatment of RA. He completes this presentation with guidance on dosing with CBD, PEA and OEA and a brief case study.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Dr Philip Blair
50
CBD Prescribing Considerations
In this presentation, family physician Dr Philip Blair MD, an experienced medicinal cannabis prescriber, will cover the different categories of diseases that are amenable to treatment with cannabidiol (CBD), and explain the mechanism of action and evidence of efficacy of CBD in several conditions. The focus of this presentation is various prescribing considerations that clinicians should take into account, including dosing and titration of CBD medicines, as well as side effects (both positive and negative) of CBD.
This presentation is targeted firmly at healthcare practitioners.
Dr Philip Blair
50
Part 1 of 2
Medical Cannabis in Treatment of Chronic Pain (Part 1)
In this learning module, we explore what medicinal cannabis is, including its history of use, the major components of cannabis (cannabidiol [CBD], tetrahydrocannabinol [THC], terpenes), and the major therapeutic actions of THC and CBD and their mechanisms of action. We also examine what people are using medicinal cannabis for, evidence of its efficacy and briefly cover safety in relation to THC and CBD.
This learning module is suitable for healthcare practitioners with an interest in learning about medicinal cannabis.
Dr Jeffrey Hergenrather
50
Part 2 of 2
Medical Cannabis in Treatment of Chronic Pain (Part 2)
In this presentation, Dr Jeffrey Hergenrather MD discusses the role of medicinal cannabis in the treatment of chronic pain, including the evidence that medicinal cannabis may be a useful adjunct or replacement to opioids and the types of collateral effects associated with medicinal cannabis treatment. Dr Hergenrather provides detailed prescribing guidelines for the use of cannabinoid medicines containing THC and CBD, including how to introduce chronic pain patients to medicinal cannabis, dosing tips for treatment of cannabis naïve patients as well as cannabis-experienced patients, and how and when to taper and reduce opioids.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Dr Jeffrey Hergenrather
50
A comprehensive on anxiety and medicinal cannabis
In this presentation, Professor Kylie O’Brien explores the scientific evidence of how our endocannabinoid system is involved in the regulation of emotions and in the pathophysiology of anxiety. She gives an overview of how CBD and THC may work in alleviating anxiety, and some of the preclinical and clinical evidence of efficacy of both in the treatment of anxiety.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Prof. Kylie O'Brien
50
Autism Spectrum Disorder & Medicinal Cannabis
Autism Spectrum Disorder is a complex behavioural condition beginning in early childhood, continuing throughout life, and the signs and symptoms occur on a spectrum. It has a complex aetiology and pathophysiology, however there is evidence that the endocannabinoid system is involved, and that medicinal cannabis might play a role in treatment. This presentation will explore what ASD is, its aetiology and pathogenesis, how the endocannabinoid system might be involved and what evidence there is that CBD and THC might be able to help treat ASD, in particular the behavioural aspects of the condition. Dosing strategies are also provided for clinicians. This is a deep dive into the science and is suitable for healthcare practitioners and those with a background in biomedical sciences.
Prof. Kylie O'Brien
50
Cannabis and Sleep
In this presentation, US trauma specialist Dr Steven Salzman MD explains the importance of addressing sleep disorders when treating chronic pain and chronic illness, with a focus on the evidence that key phytocannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) can help address insomnia, sleep apnoea and excessive daytime sleepiness. Dr Salzman gives an overview of his clinical approach in treating patients with medicinal cannabis, honed over years of treating complex chronic pain patients with a range of medical disorders.
This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Dr Steven Salzman, MD
50
Cannabinoid Therapy in Chronic Pain
In this presentation, you will learn about the types of chronic pain, mechanisms of action, comorbidities and how the endocannabinoid system is involved in modulation of chronic pain. This presentation discusses evidence from clinical studies investigating the treatment of medicinal cannabis of chronic pain, and how CBD, THC, Beta-Caryophyllene (a key terpene) and endocannabinoid-like substances palmitoylethanolamide (PEA) and Oleoylethanolamide (OEA) may be useful in treatment. Dosing recommendations are also discussed, and the presentation concludes with some case studies to illustrate how these different substances have been used in the successful treatment of chronic pain.
Dr Philip Blair
50
Created with
